The discovery of genetic mapping led to a considerable expansion of medical data knowledge or ‘big data,’ which Foley partner Richard Kaufman suggests can be properly analyzed to improve drug discovery success and reduce the cost of developing a drug. He compares genetic mapping to an exquisite tailoring of one’s personal biology that holds the potential to make drugs developed using this data much more effective and ultimately may lead to better outcomes for patients.
People
Related News
08 May 2024
In the News
Benjamin Dryden on Noncompete Ban – Expect Trade Secret Litigation Increase in ‘Volume and Nastiness’
Foley & Lardner LLP partner Benjamin Dryden offered insight on the specific impact to the manufacturing sector of the U.S. Federal Trade Commission’s (FTC) recently issued final rule banning noncompete agreements
08 May 2024
In the News
Foley Real Estate, Hospitality Transactions Highlighted in Golf Inc.
Foley & Lardner LLP served as legal advisor on two of Golf Inc.’s Top 10 Sales of 2023.
08 May 2024
In the News
Kyle Faget Assesses FDA Rule Regulating Lab-Developed Tests, Potential Challenges
Foley & Lardner LLP partner Kyle Faget offers insight on potential challenges to the U.S. Food and Drug Administration’s (FDA) final rule regulating lab-developed tests (LDTs)